Sjögren syndrome
ICD-10 M35.0 · ICD-11 4A43.2

Sjögren Syndrome with Meningoencephalitis and Active Systemic Disease

Clinical Scenario

This protocol applies to patients with Sjögren syndrome presenting with meningoencephalitis in the context of active systemic disease — a severe neurological manifestation that requires structured, evidence-based intervention.

Neurological Involvement

Central nervous system involvement in Sjögren syndrome can manifest as meningoencephalitis, myelitis, cerebral vasculitis with focal deficit, and demyelinating disease with motor deficit. When meningoencephalitis is present alongside active systemic disease, the severity of involvement directly shapes management decisions.

Treatment Approach

Management involves glucocorticoid therapy, with the specific strategy determined by disease severity.

Full dosing guidance, severity stratification, route selection, and the complete structured regimen are available via the link below.

Target: ≥3-point reduction in global ESSDAI score
Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1136/annrheumdis-2019-216114

Demyelinating disease with motor deficit; cerebral vasculitis presenting with focal deficit; myelitis; meningoencephalitis.

GCs should be used at the minimum dose and length of time necessary to control active systemic disease.

GC (recommended dose in mg/kg/day); short-term course whenever possible; consider methylprednisolone pulses in severe cases.

With respect to the definition of the therapeutic response in systemic SjS, the TF recommends using a reduction of ≥3 points in the global ESSDAI score.

View source ↗